Neima Briggs1, Michael V Gormally1, Fangyong Li2, Sabrina L Browning3, Miriam M Treggiari4, Alyssa Morrison5, Maudry Laurent-Rolle6, Yanhong Deng2, Jeanne E Hendrickson7,8, Christopher A Tormey7, Mahalia S Desruisseaux6. 1. Department of Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America. 2. Yale Center for Analytical Sciences, Yale University, New Haven, Connecticut, United States of America. 3. Section of Hematology, Department of Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, United States of America. 4. Department of Anesthesiology, Yale School of Medicine, New Haven, Connecticut, United States of America. 5. Yale School of Medicine, New Haven, Connecticut, United States of America. 6. Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America. 7. Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America. 8. Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, United States of America.
Abstract
BACKGROUND: Limited therapeutic options exist for coronavirus disease 2019 (COVID-19). COVID-19 convalescent plasma (CCP) is a potential therapeutic, but there is limited data for patients with moderate-to-severe disease. RESEARCH QUESTION: What are outcomes associated with administration of CCP in patients with moderate-to-severe COVID-19 infection? STUDY DESIGN AND METHODS: We conducted a propensity score-matched analysis of patients with moderate-to-severe COVID-19. The primary endpoints were in-hospital mortality. Secondary endpoints were number of days alive and ventilator-free at 30 days; length of hospital stay; and change in WHO scores from CCP administration (or index date) to discharge. Of 151 patients who received CCP, 132 had complete follow-up data. Patients were transfused after a median of 6 hospital days; thus, we investigated the effect of convalescent plasma before and after this timepoint with 77 early (within 6 days) and 55 late (after 6 days) recipients. Among 3,217 inpatients who did not receive CCP, 2,551 were available for matching. RESULTS: Early CCP recipients, of whom 31 (40%) were on mechanical ventilation, had lower 14-day (15% vs 23%) and 30-day (38% vs 49%) mortality compared to a matched unexposed cohort, with nearly 50% lower likelihood of in-hospital mortality (HR 0.52, [95% CI 0.28-0.96]; P = 0.036). Early plasma recipients had more days alive and ventilator-free at 30 days (+3.3 days, [95% CI 0.2 to 6.3 days]; P = 0.04) and improved WHO scores at 7 days (-0.8, [95% CI: -1.2 to -0.4]; P = 0.0003) and hospital discharge (-0.9, [95% CI: -1.5 to -0.3]; P = 0.004) compared to the matched unexposed cohort. No clinical differences were observed in late plasma recipients. INTERPRETATION: Early administration of CCP improves outcomes in patients with moderate-to-severe COVID-19, while improvement was not observed with late CCP administration. The importance of timing of administration should be addressed in specifically designed trials.
BACKGROUND: Limited therapeutic options exist for coronavirus disease 2019 (COVID-19). COVID-19 convalescent plasma (CCP) is a potential therapeutic, but there is limited data for patients with moderate-to-severe disease. RESEARCH QUESTION: What are outcomes associated with administration of CCP in patients with moderate-to-severe COVID-19infection? STUDY DESIGN AND METHODS: We conducted a propensity score-matched analysis of patients with moderate-to-severe COVID-19. The primary endpoints were in-hospital mortality. Secondary endpoints were number of days alive and ventilator-free at 30 days; length of hospital stay; and change in WHO scores from CCP administration (or index date) to discharge. Of 151 patients who received CCP, 132 had complete follow-up data. Patients were transfused after a median of 6 hospital days; thus, we investigated the effect of convalescent plasma before and after this timepoint with 77 early (within 6 days) and 55 late (after 6 days) recipients. Among 3,217 inpatients who did not receive CCP, 2,551 were available for matching. RESULTS: Early CCP recipients, of whom 31 (40%) were on mechanical ventilation, had lower 14-day (15% vs 23%) and 30-day (38% vs 49%) mortality compared to a matched unexposed cohort, with nearly 50% lower likelihood of in-hospital mortality (HR 0.52, [95% CI 0.28-0.96]; P = 0.036). Early plasma recipients had more days alive and ventilator-free at 30 days (+3.3 days, [95% CI 0.2 to 6.3 days]; P = 0.04) and improved WHO scores at 7 days (-0.8, [95% CI: -1.2 to -0.4]; P = 0.0003) and hospital discharge (-0.9, [95% CI: -1.5 to -0.3]; P = 0.004) compared to the matched unexposed cohort. No clinical differences were observed in late plasma recipients. INTERPRETATION: Early administration of CCP improves outcomes in patients with moderate-to-severe COVID-19, while improvement was not observed with late CCP administration. The importance of timing of administration should be addressed in specifically designed trials.
Authors: Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405
Authors: Eric Salazar; Katherine K Perez; Madiha Ashraf; Jian Chen; Brian Castillo; Paul A Christensen; Taryn Eubank; David W Bernard; Todd N Eagar; S Wesley Long; Sishir Subedi; Randall J Olsen; Christopher Leveque; Mary R Schwartz; Monisha Dey; Cheryl Chavez-East; John Rogers; Ahmed Shehabeldin; David Joseph; Guy Williams; Karen Thomas; Faisal Masud; Christina Talley; Katharine G Dlouhy; Bevin V Lopez; Curt Hampton; Jason Lavinder; Jimmy D Gollihar; Andre C Maranhao; Gregory C Ippolito; Matthew O Saavedra; Concepcion C Cantu; Prasanti Yerramilli; Layne Pruitt; James M Musser Journal: Am J Pathol Date: 2020-05-27 Impact factor: 4.307
Authors: Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray Journal: N Engl J Med Date: 2020-07-17 Impact factor: 91.245
Authors: Katharine J Bar; Pamela A Shaw; Grace H Choi; Nicole Aqui; Andrew Fesnak; Jasper B Yang; Haideliza Soto-Calderon; Lizette Grajales; Julie Starr; Michelle Andronov; Miranda Mastellone; Chigozie Amonu; Geoff Feret; Maureen DeMarshall; Marie Buchanan; Maria Caturla; James Gordon; Alan Wanicur; M Alexandra Monroy; Felicity Mampe; Emily Lindemuth; Sigrid Gouma; Anne M Mullin; Holly Barilla; Anastasiya Pronina; Leah Irwin; Raeann Thomas; Risa A Eichinger; Faye Demuth; Eline T Luning Prak; Jose L Pascual; William R Short; Michal A Elovitz; Jillian Baron; Nuala J Meyer; Kathleen O Degnan; Ian Frank; Scott E Hensley; Donald L Siegel; Pablo Tebas Journal: J Clin Invest Date: 2021-12-15 Impact factor: 14.808
Authors: Javier Mariani; Laura Antonietti; Carlos Tajer; León Ferder; Felipe Inserra; Milagro Sanchez Cunto; Diego Brosio; Fernando Ross; Marcelo Zylberman; Daniel Emilio López; Cecilia Luna Hisano; Sebastián Maristany Batisda; Gabriela Pace; Adrián Salvatore; Jimena Fernanda Hogrefe; Marcela Turela; Andrés Gaido; Beatriz Rodera; Elizabeth Banega; María Eugenia Iglesias; Mariela Rzepeski; Juan Manuel Gomez Portillo; Magalí Bertelli; Andrés Vilela; Leandro Heffner; Verónica Laura Annetta; Lucila Moracho; Maximiliano Carmona; Graciela Melito; María José Martínez; Gloria Luna; Natalia Vensentini; Walter Manucha Journal: PLoS One Date: 2022-05-27 Impact factor: 3.752
Authors: Artur Belov; Yin Huang; Carlos H Villa; Barbee I Whitaker; Richard Forshee; Steven A Anderson; Anne Eder; Nicole Verdun; Michael J Joyner; Scott R Wright; Rickey E Carter; Deborah T Hung; Mary Homer; Corey Hoffman; Michael Lauer; Peter Marks Journal: Am J Hematol Date: 2022-03-24 Impact factor: 13.265
Authors: Jasmina Grujić; Nevenka Bujandrić; Zorana Budakov-Obradović; Vladimir Dolinaj; Damir Bogdan; Nebojša Savić; Alejandro Cabezas-Cruz; Dragana Mijatović; Verica Simin; Nikola Anđelić; Pavle Banović Journal: Int J Environ Res Public Health Date: 2021-12-21 Impact factor: 3.390